0.69
-2.83%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Telomir Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Telomir Pharmaceuticals is based in Miami, Florida and is incorporated in Florida. Its shares trade on Nasdaq under the ticker TELO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $10.4m. At that date it held total assets of $7.3m and shareholders' equity of $5.9m.
Ratio is calculated using the relative company valuations of each of TELO and TELI, as determined by Moore (as further described herein).
Glucose Clearance: Significant improvements in OGTT results highlighted Telomir-1’s impact on glucose metabolism.
NIDDM by studying the effect of Telomir-1 on several metabolic parameters in a rat model of NIDDM. These studies are ongoing.
Biological Aging: The study demonstrated a measurable reversal of biological age markers in subjects treated with Telomir-1.
Telomir-1’s impact on retinal degeneration and Drusen formation caused by metal accumulation.
These indications are being carefully evaluated to identify the most impactful opportunities for clinical development and market entry.
Quoted from its 10-K, filed 17 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Feb 2024
- Employees
- 2
- Website
- telomirpharma.com ↗
- Head office
- 100 SE 2ND ST, MIAMI, FL, 33131
- Incorporated in
- FL
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Erez AminovChairman of the Board, Chief Executive Officer, since 2024
- Mr. Alan WeichselbaumChief Financial Officer
- Dr. Matthew Del GiudiceDirector
- Mr. Ned MacphersonDirector
- Mr. Matthew WhalenDirector
- Dr. Craig EagleIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company has a pre-clinical-stage focus with a novel small molecule TELOMIR-1.
- TELOMIR-1 functions as an oral in situ therapeutic treatment for human stem cells.
- The BioMAP platform offers an unbiased, target-agnostic approach to understanding therapies.
Weaknesses
- The company employs only 2 full-time employees.
- The company is in the pre-clinical stage with no commercialized products.
- The company went public via IPO in 2024 with limited operational history.
Opportunities
- TELOMIR-1 has potential applications for age-related inflammatory conditions like hemochromatosis.
- The BioMAP platform could support development of combination therapies.
- The company may expand its focus to post-chemotherapy recovery treatments.
Threats
- The pre-clinical stage of development poses significant regulatory and commercialization risks.
- Limited employee count may hinder research and development capabilities.
- The company's IPO in 2024 indicates a lack of established market presence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.